At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 5 enrolled
Drug / intervention
[18F]F-AraG Imagingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of [18F]F-AraG Pharmacokinetics in Tumors and Non-Malignant Tissue Using Dynamic Total Body PET Imaging in Healthy Subjects and in Patients With Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Early Phase 1 clinical trial evaluating [18F]F-AraG Imaging for Lung Cancer, Nonsmall Cell. Completed, enrolled 5 participants across 1 site.
Detailed Summary
In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo \[18F\]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Nonsmall Cell
CountriesUnited States
CollaboratorsCellSight Technologies, Inc.
Timeline
Early Ph 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionFeb 2023
TodayJul 2026
First PostedDec 22, 2020
Enrollment StartMar 31, 2021
Primary CompletionFeb 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.5 years ago
Interventions
[18F]F-AraG Imagingdrug
Total body PET imaging using \[18F\]F-AraG